Healing the System: MAPS' Audacious Plan for Psychedelic Justice

WASHINGTON, June 02, 2026 – As psychedelic-assisted therapy inches closer to mainstream medicine, a profound and uncomfortable question looms: What becomes of the people most ravaged by the very drug policies these therapies seek to transcend? The Multidisciplinary Association for Psychedelic Studies (MAPS), a four-decade veteran in the fight for psychedelic science, is confronting this question head-on with an initiative that could redefine the intersection of healing, justice, and innovation.

Today, MAPS announced its Psychedelics for System-Impacted People (PSIP) project, a far-reaching effort to explore how psychedelic healing can be responsibly applied to the millions of Americans bearing the mental and emotional scars of the criminal legal system. The project launches not with a clinical trial, but with a foundational literature review, “Relocating the Root,” signaling a deliberate, systems-based approach to a problem riddled with complexity. It’s a strategic move to build a new operational model for healing, one designed from the ground up with, and for, a population that traditional systems have consistently failed.

Relocating the Root of Trauma

The scale of the mental health crisis within system-impacted communities is staggering. According to Bureau of Justice Statistics data, nearly half of all people in jails and prisons have a history of mental illness, rates far exceeding the general population. These individuals often enter the system with pre-existing conditions like PTSD, depression, and substance use disorders, frequently stemming from adverse childhood experiences. Incarceration itself then acts as an accelerant, compounding trauma in an environment devoid of adequate care.

“Relocating the Root” synthesizes this grim reality, but its most disruptive contribution is its critique of the diagnostic tools used to understand it. The review argues that frameworks like the DSM-5, designed without these communities in mind, may inadvertently pathologize natural psychological responses to systemic racism and structural violence. It’s a challenge to the entire diagnostic paradigm, suggesting that before we can treat, we must first correctly identify the injury—and its source.

“Efforts to change psychedelic drug policy are happening in the shadow of the War on Drugs,” said Sia Henry, J.D., MAPS Associate Director of Policy and a key leader of the project. “System-impacted people, especially those of color, have largely been left out of this conversation despite their high prevalence of trauma, substance use disorders, and other complex mental health needs. That has to change.” Henry, an attorney with deep experience in criminal justice reform and restorative justice, embodies the project’s ethos. “We are asking what safety, dignity, and healing look like from the perspective of those most harmed by the criminal legal system, and allowing those answers to shape research, policy, and practice from the start.”

A Strategic Partnership for Community-Led Innovation

Recognizing that a new approach requires new partnerships, the second phase of PSIP is a qualitative research study conducted with the Center for Collective Healing (CCH), a decentralized research institute between Yale and Howard University. This collaboration is the project's operational core, designed to ensure the work is not just about the community, but led by it.

Instead of a traditional, top-down clinical trial, MAPS and CCH are raising funds for a study built on listening. The plan involves paid focus groups with formerly-incarcerated people of color, co-facilitated by CCH researchers and consultants with lived experience of incarceration. The goal is to understand their self-identified mental health needs, their concerns about psychedelics, and what conditions would be necessary for them to feel safe participating in such healing modalities. This methodology is a deliberate departure from standard research protocols, which have historically excluded individuals with the complex co-morbidities and socioeconomic instability common in this population, thereby creating a massive evidence gap.

“Community-grounded research begins by listening,” stated AZA Allsop, M.D., Ph.D., Director of the Center for Collective Healing. “This collaboration is intended to create a process where formerly-incarcerated people can name what they need, what concerns they have, and what safeguards would be necessary before psychedelic-assisted healing is even considered.” For leaders watching the burgeoning psychedelic industry, this is a crucial lesson in product development and market-entry for sensitive technologies. As Dr. Allsop notes, “If the movement wants to translate promise into practice, it will have to figure out how to bring everyone along, or risk becoming a shadow of the commitment to human potential that birthed it.”

Confronting the Post-Prohibition Paradox

The PSIP project also serves as a high-stakes stress test for the legal and ethical infrastructure of a post-prohibition world. As MAPS Co-Executive Director Ismail L. Ali, J.D., bluntly puts it, “Legal access is not the same as equitable access.” This is the central paradox that the initiative forces into the open.

Imagine a scenario, just over the horizon, where MDMA-assisted therapy is an FDA-approved treatment for PTSD. A formerly incarcerated person on parole, struggling with trauma directly related to their time in prison, could be a perfect candidate. Yet, participating in this legal, medical treatment could trigger a positive result on a mandatory drug test, violating their parole and sending them back to prison. This is not a hypothetical; it is the predictable outcome of layering a 21st-century therapeutic innovation onto a 20th-century punitive legal framework.

The PSIP project is systematically cataloging these points of failure, examining legal barriers like parole and probation conditions, drug testing, employment restrictions, and the pervasive risk of state surveillance. By identifying these systemic conflicts now, MAPS aims to drive policy reform that can create genuine pathways to care, not just the illusion of it.

This work is a direct expression of MAPS’s evolution. Having incubated Lykos Therapeutics (now Resilient Pharmaceuticals) and shepherded MDMA therapy to the cusp of FDA approval, the organization is now leveraging its position to address the market’s most glaring externalities. “Building a post-prohibition future rooted in health, consent, dignity, and repair is the work still in front of us,” Ali affirmed. This initiative is an attempt to build an operating system for that future, ensuring that the people who paid the highest price for the War on Drugs are not once again left behind in the peace.